Evidence analysisNovember 6, 2026Health & Science
Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Date of authorisation: 09/06/2003, Revision: 28, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Aldurazyme is a medicinal enzyme replacement therapy containing the active substance laronidase. It is approved in the European Union for the treatment of mucopolysaccharidosis I (MPS I), a rare inherited metabolic disorder caused by a deficiency in the enzyme ?-L iduronidase. In patients with MPS I, this enzymatic deficiency leads to accumulation of glycosaminoglycans (GAGs) in body tissues and organs, causing progressive damage.
The medication is administered via weekly intravenous infusions, typically in a hospital setting with appropriate medical supervision due to risks of allergic or infusion-related reactions. It is intended for long-term use for controlling non-neurological symptoms of MPS I such as enlarged liver, joint stiffness, reduced lung function, heart, and eye complications.
Clinical studies reviewed by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) showed improvements in lung function, walking ability, and reductions in GAG levels and liver size in children. The safety profile includes infusion-related reactions, some severe but generally decreasing with continued use. Almost all treated patients develop antibodies to laronidase, but the implications for safety and efficacy remain uncertain.
The drug received marketing authorization in the EU on June 10, 2003, initially under exceptional circumstances due to limited available data at that time. Additional data supplied by the company later led to revocation of this exceptional status in 2015.
What the source claims
- Aldurazyme is indicated specifically to treat non-neurological manifestations of MPS I.
- The enzyme, produced by recombinant DNA technology, replaces the deficient enzyme in patients and helps control the accumulation of harmful substances in tissues.
- In clinical trials, the medicine demonstrated improved forced vital capacity (FVC) and 6-minute walk test distance after 26 weeks compared to placebo, with sustained benefits up to four years.
- In children under 5 years, Aldurazyme significantly reduced urinary GAG levels (~60%) and normalized liver size in 50% of treated patients after one year.
- Infusion-related reactions are the most common adverse effects, including fever, rash, pain, and flushing, but these tend to diminish over time.
- Nearly all patients develop anti-laronidase antibodies; however, the source asserts that the clinical impact remains unclear.
- The CHMP concluded that Aldurazyme’s benefits outweigh its risks based on the presented data.
What may be missing from the usual framing
The publicly available assessment does not deeply explore the long-term impact of antibody formation on treatment efficacy or safety, a potentially important consideration in enzyme replacement therapies. Nor does it comprehensively discuss neurological symptoms of MPS I, as Aldurazyme is not indicated for these manifestations, leaving a gap in understanding comprehensive disease management options.
The source also does not address alternative or adjunctive therapies, patient quality of life measures beyond functional tests, or cost and accessibility issues that often accompany rare disease treatments. There is limited information on patient heterogeneity and how responses might vary across different clinical presentations or genotypes of MPS I.
Competing evidence or uncertainty
The evidence summarized by the EMA primarily derives from relatively small clinical trials due to the rarity of MPS I, which inherently limits statistical power. This creates uncertainty about the consistency and generalizability of the benefits observed. The evolution of treatment outcomes beyond four years is insufficiently documented in the provided data.
The frequent antibody response raises questions about possible reduced efficacy or increased adverse events over time, yet definitive evidence remains lacking. There is also limited peer-reviewed analysis openly comparing Aldurazyme with other emerging therapies such as hematopoietic stem cell transplantation or investigational gene therapies. The source therefore leaves room for interpretation and further investigation.
Why it matters
For patients with MPS I, a progressive and potentially life-threatening condition, Aldurazyme offers a targeted therapy that can meaningfully ameliorate many non-neurological symptoms and help to improve functional capacity. Understanding the balance of benefits, risks, and limitations of this enzyme replacement therapy is crucial for patients, healthcare providers, and policymakers to make informed decisions about treatment strategies and resource allocation.
The rarity of the disease and the complexity of treatment highlight challenges in accumulating robust data, underscoring the importance of ongoing monitoring and research. Additionally, the high cost typical of such specialized therapies raises considerations about accessibility and equity in healthcare systems.
What to verify next
- Long-term clinical outcomes beyond four years of Aldurazyme treatment.
- The clinical significance of antibody formation against laronidase in diverse patient populations.
- Comparative effectiveness of Aldurazyme versus other treatment modalities, including gene therapy and stem cell transplantation.
- Impact of Aldurazyme on patient-centered outcomes such as quality of life and daily functioning.
- Access, pricing, and reimbursement policies affecting availability in different healthcare settings.
- New research or updated regulatory assessments post-2026 regarding safety and efficacy profiles.
Readers interested in detailed clinical data and regulatory assessments should consult the original European Medicines Agency documents and related peer-reviewed literature for comprehensive understanding.
Source & verification
Primary source: What's new · November 6, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…